Myofibroblast matrix metalloproteinases activate the neutrophil chemoattractant CXCL7 from intestinal epithelial cells.

BACKGROUND & AIMS The up-regulation of matrix metalloproteinases (MMPs) in the inflamed gut has mainly been associated with mucosal degradation and ulceration. However, their in vitro capacity to specifically cleave inflammatory mediators indicates that MMPs may have a profound immunoregulatory impact. We hypothesized that MMPs proteolytically modify intestinal epithelial chemokine signaling. METHODS Interleukin-1beta-stimulated Caco-2 cells were exposed basolaterally to nanomolar concentrations of activated MMP-3 or cocultured with interleukin-1beta-stimulated, MMP-producing, colonic myofibroblasts (CCD-18co). The conditioned media were subjected to chemotaxis assays. In addition, epithelial cells from patients with colitis were examined by real-time polymerase chain reaction, immunoblotting, and immunohistochemistry. RESULTS MMP-3 dose-dependently induced the neutrophil (up to 5-fold) but not monocyte chemoattractant capacity of Caco-2 cells. A similar Caco-2 chemotactic response was obtained in the Caco-2/CCD-18co cocultures. The principal mediator of these protease-related effects was identified as the potent neutrophil chemokine CXCL7 (neutrophil activating peptide 2), a proteolytic cleavage product of chemotactically inert platelet basic protein (PBP), not previously identified in the intestine. Antibodies against CXCL7 inhibited the MMP-induced chemotactic response by 84%, and PBP mRNA and protein were detected in stimulated Caco-2 but not in CCD-18co cells. Furthermore, PBP transcript and protein levels were low in the mucosa and in isolated epithelial cells from patients with Crohn's disease and from normal intestine but increased up to 13-fold in patients with ulcerative colitis. CONCLUSIONS These findings identify a novel proinflammatory action of MMPs in inflammation and suggest that lamina propria myofibroblasts are required to achieve maximal intestinal epithelial immune activation.

[1]  William C. Parks,et al.  Matrix metalloproteinases as modulators of inflammation and innate immunity , 2004, Nature Reviews Immunology.

[2]  S. Husson,et al.  Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. , 2003, European journal of biochemistry.

[3]  H. Verspaget,et al.  Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease , 2003, The Journal of pathology.

[4]  P. E. Van den Steen,et al.  Gelatinase B/matrix metalloproteinase‐9 cleaves interferon‐β and is a target for immunotherapy , 2003 .

[5]  Jennifer M. Smith,et al.  Immunobiology of epithelial chemokines in the intestinal mucosa. , 2003, Surgery.

[6]  S. Watson,et al.  Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. , 2003, The American journal of pathology.

[7]  Penny A. Johnson,et al.  Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease , 2003, The Journal of pathology.

[8]  J. Madara,et al.  Intestinal epithelial pathobiology: past, present and future. , 2002, Best practice & research. Clinical gastroenterology.

[9]  M. Selsted,et al.  Antimicrobial Peptides from Human Platelets , 2002, Infection and Immunity.

[10]  T. Macdonald,et al.  Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation , 2002, Gut.

[11]  Takanori Aoki,et al.  Matrix Metalloproteinases Cleave Connective Tissue Growth Factor and Reactivate Angiogenic Activity of Vascular Endothelial Growth Factor 165* , 2002, The Journal of Biological Chemistry.

[12]  J. Wallace,et al.  Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. , 2002, Blood.

[13]  Constance E. Brinckerhoff,et al.  Matrix metalloproteinases: a tail of a frog that became a prince , 2002, Nature Reviews Molecular Cell Biology.

[14]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[15]  C. Overall,et al.  Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1* , 2001, The Journal of Biological Chemistry.

[16]  X. Wen,et al.  Evidence for Epigenetic Mechanisms That Silence Both Basal and Immune-Stimulated Transcription of the IL-8 Gene1 , 2001, The Journal of Immunology.

[17]  T. Macdonald,et al.  Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[18]  P. E. Van den Steen,et al.  Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. , 2000, Blood.

[19]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[20]  H. Flad,et al.  The β‐thromboglobulins and platelet factor 4: blood platelet‐derived CXC chemokines with divergent roles in early neutrophil regulation , 2000, Journal of leukocyte biology.

[21]  B. Fingleton,et al.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.

[22]  C. J. Taylor,et al.  Matrix metalloproteinase levels are elevated in inflammatory bowel disease. , 1999, Gastroenterology.

[23]  R. Macdermott,et al.  Molecular Medicine © 1999 The Picower Institute Press Butyrate Switches the Pattern of Chemokine Secretion by Intestinal Epithelial Cells through , 2022 .

[24]  K. Brandt,et al.  Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. , 1999, Arthritis and rheumatism.

[25]  T. Macdonald,et al.  A major role for matrix metalloproteinases in T cell injury in the gut. , 1997, Journal of immunology.

[26]  Y. Sasaguri,et al.  Degradation of Interleukin 1β by Matrix Metalloproteinases* , 1996, The Journal of Biological Chemistry.

[27]  J. Seltzer,et al.  Comparison of cleavage site specificity of gelatinases A and B using collagenous peptides. , 1996, Biochimica et biophysica acta.

[28]  K. Suzuki,et al.  Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. , 1994, The Journal of biological chemistry.

[29]  A. H. Drummond,et al.  Processing of tumour necrosis factor-α precursor by metalloproteinases , 1994, Nature.

[30]  M. Baggiolini,et al.  Both interleukin‐8 receptors independently mediate chemotaxis , 1994 .

[31]  G. Evans,et al.  A low-temperature method for the isolation of small-intestinal epithelium along the crypt-villus axis. , 1991, The Biochemical journal.